Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Ikaria Holdings, a fully integrated critical care biopharmaceutical company, has appointed Daniel Tasse as president and CEO.
Subscribe to our email newsletter
Mr. Tasse succeeds David Shaw, who has served as chairman and interim CEO since the creation of Ikaria in March 2007 and will now serve as executive chairman and chairman of the Board. Mr. Tasse most recently served as the general manager of Baxter International’s $2 billion Pharmaceuticals & Technologies business, a division created by integrating the company’s Anesthesia, Critical Care and BioPharma Solutions Business units.
David Shaw, chairman of the board, Ikaria, said: “We expect to benefit strategically and operationally from Daniel’s many years of involvement in both drugs and devices across many therapeutic areas and healthcare settings, including critical care.”